References
- Kumar S, Noronha V, Chu E. Pharmacology of cancer chemotherapy. Cancer: Principles & Practice of Oncology7th edn, V T DeVita, Jr, S Hellman, S A Rosenberg. Lippincott Williams & Wilkins, Philadelphia 2005; 366
- Conrad M E. Cytarabine and cardiac failure. Am J Hematol 1992; 41: 143–144
- Willemze R, Zwaan F E, Colpin G, Keuning J J. High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 1982; 29: 141–146
- Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984; 144: 1868–1869
- Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995; 19: 141–144
- Hermans C, Straetmans N, Michaux J L, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997; 75: 55–57
- Stamatopoulos K, Kanellopoulou G, Vaiopoulos G, Stamatellos G, Yataganas X. Evidence for sinoatrial blockade associated with high dose cytarabine therapy. Leuk Res 1998; 22: 759–761
- Yamada T, Tsurumi H, Hara T, Sawada M, Oyama M, Moriwaki H. Cytarabine-induced pericarditis. Rinsho Ketsueki 1998; 39: 1115–1120
- Gahler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 2003; 26: 348–350
- Kumagawa M, Suzuki K, Nagano M, Takamatsu Y, Suzumiya J, Tamura K. High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16) (p13q22). Rinsho Ketsueki 2003; 44: 404–406
- Floyd J D, Nguyen D T, Lobins R L, Bashir Q, Doll D C, Perry M C. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685–7696
- Pai V B, Nahata M C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263–302